Novo Nordisk : Disappointing phase IIa results for monlunabant in obesity
>Limited efficacy and a questionable safety profile - On Friday, Novo published the initial results of its drug candidate, monlunabant, developed for the treatment of obesity. This phase IIa trial studied the weight loss and safety of a daily dose of 10 mg, 20 mg and 50 mg of monlunabant compared with a placebo arm after 16 weeks in 243 people suffering from obesity.Unfortunately, the results raise a number of questions at this stage: i/ limited efficacy: we...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.